trial · primary record
Ocrelizumab
Multiple Sclerosis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 500 |
| Primary completion | 2029-12-31 |
| Primary endpoint | Change From Baseline to End of Study in the Physical Functioning Score of the Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) |
| Registry ID | NCT06675955 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:08.381Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06675955
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ocrelizumab · compound